Slashdot Mirror
Domain: cancer.gov
Stories and comments across the archive that link to cancer.gov.
Stories · 3
-
FDA Approves First Cell-Based Therapy For Cancer (npr.org)
An anonymous reader quotes a report from NPR: The Food and Drug Administration on Wednesday announced what the agency calls a "historic action" -- the first approval of a cell-based gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a "living drug" because it involves using genetically modified immune cells from patients to attack their cancer. The drug was approved to treat children and young adults suffering from acute lymphoblastic leukemia, a cancer of blood and bone marrow that is the most common childhood cancer in the United States. About 3,100 patients who are 20 and younger are diagnosed with ALL each year. The treatment involves removing immune system cells known as T cells from each patient and genetically modifying the cells in the laboratory to attack and kill leukemia cells. The genetically modified cells are then infused back into patients. It's also known as CAR-T cell therapy.
The treatment, which is also called CTL109, produced remission within three months in 83 percent of 63 pediatric and young adult patients. The patients had failed to respond to standard treatments or had suffered relapses. Based on those results, an FDA advisory panel recommended the approval in July. The treatment does carry risks, however, including a dangerous overreaction by the immune system known as cytokine-release syndrome. As a result, the FDA is requiring strong warnings. -
FDA Approves First Cell-Based Therapy For Cancer (npr.org)
An anonymous reader quotes a report from NPR: The Food and Drug Administration on Wednesday announced what the agency calls a "historic action" -- the first approval of a cell-based gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a "living drug" because it involves using genetically modified immune cells from patients to attack their cancer. The drug was approved to treat children and young adults suffering from acute lymphoblastic leukemia, a cancer of blood and bone marrow that is the most common childhood cancer in the United States. About 3,100 patients who are 20 and younger are diagnosed with ALL each year. The treatment involves removing immune system cells known as T cells from each patient and genetically modifying the cells in the laboratory to attack and kill leukemia cells. The genetically modified cells are then infused back into patients. It's also known as CAR-T cell therapy.
The treatment, which is also called CTL109, produced remission within three months in 83 percent of 63 pediatric and young adult patients. The patients had failed to respond to standard treatments or had suffered relapses. Based on those results, an FDA advisory panel recommended the approval in July. The treatment does carry risks, however, including a dangerous overreaction by the immune system known as cytokine-release syndrome. As a result, the FDA is requiring strong warnings. -
Biden Unveils Open-Access Database To Advance Cancer Research (go.com)
An anonymous reader quotes a report from ABC News: Vice President Joe Biden unveiled a public database for clinical data on cancer on Monday that aims to help researchers and doctors better tailor new treatments to individuals. Overseen by the National Cancer Institute, the Genomic Data Commons starts with genomic and clinical data for 12,000 patients. The system is designed to increase sharing of information about the gene sequences of tumors and how patients with those tumors responded to specific treatments. "The information is scattered among different government and academic repositories. Most of it is out of the reach of scientists," Biden said. "We're bringing it into one space." Though easily searchable, the database includes protections for privacy and security, Biden said. He urged cancer experts gathered in Chicago to "upload your raw genomic data" to the system for use by fellow researchers. "All of you know it's the right thing to do," Biden said. "It's the quickest way for us to move forward. And it's not technically hard for us to do it." You can read the key features of the GDC via The White House here.